Vicarious Surgical INC 8-K filings

Vicarious Surgical Inc. has filed a Form 8-K announcing the approval of a general assignment for the benefit of creditors and a plan of dissolution, leading to the resignation of its board and termination of key executives.

Vicarious Surgical Inc. announced the resignation of Chief Financial Officer Sarah Romano, effective July 22, 2026.

Vicarious Surgical Inc. announced that its stockholders approved an amendment to its Certificate of Incorporation to effect a reverse stock split.

Vicarious Surgical Inc. announced executive salary reductions for its President and CTO, coinciding with its delisting from the NYSE.

Vicarious Surgical Inc. announced its Class A common stock will be delisted from the NYSE due to falling below the minimum market capitalization requirement, with trading suspended and a move to the OTCID market tier.

Vicarious Surgical Inc. has updated the severance and change-in-control agreements for its CEO, Stephen From, and CFO, Sarah Romano, enhancing their termination benefits.

Vicarious Surgical Inc. stockholders overwhelmingly approved the exercise of warrants to purchase up to 2.3 million Class A common shares at a special meeting held on January 9, 2026.

Vicarious Surgical announced an At-The-Market offering, the delisting of its warrants from the NYSE, and a reduced cash burn guidance for 2026.

Vicarious Surgical announced a $5 million reduction in its 2025 cash burn outlook to $45 million, alongside board resignations and new committee appointments.

Vicarious Surgical Inc. announced third quarter 2025 financial results, showing reduced operating expenses and a recent $5.9 million capital raise.

Vicarious Surgical Inc. announced the pricing of a $5.9 million registered direct offering and concurrent private placement of common stock and warrants with an institutional investor.

Vicarious Surgical Inc. announced the appointment of Joseph Doherty, an experienced healthcare and medical device executive, as the new Chairman of its Board of Directors.

Vicarious Surgical updated its investor presentation, highlighting significant progress in its single-port robotic surgical system and its path to commercialization.

Vicarious Surgical Inc. announced the resignation of Donald Tang from its Board of Directors and the appointment of Victoria Carr-Brendel to the Audit Committee, effective September 12, 2025.

Vicarious Surgical updated its investor presentation, highlighting significant progress in developing its single-port surgical robot and outlining key milestones towards commercialization.

Vicarious Surgical Inc. reported a reduced net loss for the second quarter of 2025 and announced Stephen From as its new Chief Executive Officer.

Vicarious Surgical Inc. announced the appointment of Stephen From as its new Chief Executive Officer, effective August 7, 2025, with co-founder Adam Sachs transitioning to the role of President.

Vicarious Surgical Inc. received NYSE acceptance for its plan to regain compliance with listing standards after falling below market capitalization and stockholders' equity thresholds, while also dismissing Deloitte & Touche LLP and engaging Cherry Bekaert LLP as its new independent auditor amidst ongoing material weaknesses in internal controls.

Vicarious Surgical Inc. announced stockholder approval of an expanded equity incentive plan and changes to its non-employee director compensation policy, alongside the election of new directors Fuad Ahmad and Joseph Doherty at its 2025 Annual Meeting.

Vicarious Surgical announced its Q1 2025 financial results and highlighted progress towards becoming a clinical-stage company.

Vicarious Surgical received a notice from the NYSE indicating non-compliance with continued listing standards due to its market capitalization and stockholders' equity falling below $50 million.

Vicarious Surgical announces that President Randy Clark will transition to a Board Member role, effective April 25, 2025, pending customary conflict checks.

Vicarious Surgical announces completion of Version 1.0 system integration, progress towards first clinical use, and provides 2025 cash burn guidance of $50 million.

Vicarious Surgical Inc. announced the appointment of Sarah Romano as Chief Financial Officer, effective April 1, 2025, to lead the company's financial strategy and corporate development.

Vicarious Surgical announces the retirement of Chief Operating Officer John Mazzola, effective April 1, 2025, with his responsibilities transitioning to Company President Randy Clark.

Vicarious Surgical Inc. has entered into a consulting agreement with its former Chief Financial Officer, William Kelly, following his departure from the role.

Vicarious Surgical's Chief Financial Officer, William Kelly, will depart on January 2, 2025, after nearly four years with the company.

Vicarious Surgical announced its Q3 2024 financial results, highlighting a decrease in operating expenses and progress towards its Version 1.0 System integration milestone.

Vicarious Surgical announced a 17% decrease in operating expenses and progress towards their V1.0 integration milestone in their second quarter 2024 financial results.

Vicarious Surgical Inc. has completed a 1-for-30 reverse stock split and increased the number of shares available under its equity incentive plan following shareholder approval at its annual meeting.